| Literature DB >> 26787685 |
Simona Hogas1, Adalbert Schiller2, Luminita Voroneanu3, Daniela Constantinescu4, Romulus Timar5, Petru Cianga4, Dimitrie Siriopol1, Flaviu Bob2, Corina Cianga4, Mihai Onofriescu1, Florica Gadalean2, Mihai Hogas6, Adelina Mihaescu2, Stefana Catalina Bilha7, Bogdan Timar5, Mehmet Kanbay8, Maciej Banach9, Adrian Covic1.
Abstract
Patients with end-stage renal disease (ESRD) have an increased risk of all-cause mortality. The prognostic value of the new cardiac biomarkers, cardiotrophin 1 (CT-1) and galectin 3 (GAL-3), has not yet been defined in hemodialysis (HD) patients. The aim of this study was to determine the use of these novel biomarkers for predicting mortality in HD patients. Plasma GAL-3 and CT-1 concentrations were determined (at baseline) in 88 HD patients followed for 22.2 ± 4.7 months. During the follow-up period, 21 (23.9%) deaths were recorded. According to Cox analysis, the cutoff point for GAL-3 as a predictor of mortality was 23.73 ng/mL, while the cutoff point for CT-1 as a predictor of mortality was 36 pg/mL. In univariate analysis, only GAL-3 >23.73 ng/mL was an independent predictor of mortality (hazard ratio 2.60; 95% confidence interval, 1.09-6.18). In a multivariable Cox proportional hazards model, GAL-3 levels above the cutoff value remained an independent predictor of all-cause mortality. Our data suggest that similar to the general population, GAL-3 is an independent predictor of mortality in HD patients.Entities:
Keywords: cardiotrophin 1; chronic kidney disease; galectin 3; hemodialysis; mortality
Mesh：
Substances：
Year: 2016 PMID： 26787685 DOI： 10.1177/0003319715623397
Source DB: PubMed Journal: Angiology ISSN： 0003-3197 Impact factor: 3.619